Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-1 (of 1 Records) |
Query Trace: Chang GJJ[original query] |
---|
Can reductions in the cross-reactivity of flavivirus structural proteins lead to improved safety and immunogenicity of tetravalent dengue vaccine?
Chao DY , Crill WD , Davis BS , Chang GJJ . Future Virol 2015 10 (5) 477-480 The most advanced dengue vaccine in clinical development is the tetravalent chimeric yellow fever-17D dengue (TCYD) vaccine. Optimistically, this vaccine could be available globally in the very near future, which may potentially reduce the burden of dengue disease [1]. The TCYD vaccine was estimated to achieve 56% efficacy based on primary end point calculations from two Phase III efficacy trials in Asia and Latin America and the efficacies were higher among trial participants with prior dengue virus (DENV) exposure [2]. Several concerns have been raised due to unexpected lower overall efficacy for all DENV serotypes, particularly for DENV-2 [3,4]; thus, there is a need to develop second-generation dengue vaccines to improve efficacy of the current TCYD vaccine. There are other dengue vaccine candidates in clinical trial and research development, but none of them are attempting to modulate the immune responses to improve the vaccine safety and efficacy. In this editorial, we will discuss the principle of immune modulation based on cross-reactivity reduction (CRR) immunogens and the rationale of this approach in the development of second-generation tetravalent dengue vaccine. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure